Mediation of renal vascular effects of epidermal growth factor by arachidonate metabolites
- 1 April 1990
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 4 (6) , 1654-1660
- https://doi.org/10.1096/fasebj.4.6.2138579
Abstract
In the rat, intrarenal infusion of epidermal growth factor decreases renal blood flow and glomerular filtration rate, and epidermal growth factor (EGF) induces contraction of cultured rat mesangial cells. The present studies examined the role of arachidonic acid metabolites in this response. Intrarenal EGF infusion increased urinary iPGF2α by 300%, and in isolated glomeruli EGF stimulated iPGF2α by 38%, but did not affect thromboxane B2 production. Furthermore, the thromboxane A2 receptor antagonist, SQ29548, did not block EGF's vasoconstrictive effects. After selective cyclooxygenase inhibition with ibuprofen, intrarenal EGF infusion no longer produced local vasoconstriction but instead led to systemic vasodilation (SBP: 117 ± 10 vs. 98 ± 7; n = 5; P < 0.05) that was accompanied by significant increases in RPF (3.8 ± 0.4 vs. 5.6 ± 0.2; P < 0.01) and glomerular filtration rate (0.9 ± 0.1 vs. 1.1 ± 0.1; P < 0.05). When total arachidonate metabolism was inhibited by the additional administration of 5,8,11,14-eicosatetraynoic acid, the EGF-induced vasodilation observed during cyclooxygenase inhibition alone was abolished, and vasoconstrictor responses to EGF were again noted. Similar effects were noted with concomitant administration of the C-P450 inhibitor ketoconazole. EGF's vasoconstrictive effects were unaltered by the simultaneous administration of the angiotensin II antagonist saralasin. Thus, the renal hemodynamic responses to EGF are mediated in part by arachidonic acid metabolites. Cyclooxygenase inhibition unmasks a potent renal and systemic vasodilator action of EGF owing to its stimulation of systemic release of noncyclooxygenase arachidonate metabolites.— Harris, R. C.; Munger, K. A.; Badr, K. F.; Takahashi, K. Mediation of renal vascular effects of epidermal growth factor by arachidonate metabolites. FASEB J. 4: 1654-1660; 1990.Keywords
This publication has 28 references indexed in Scilit:
- Effect of epidermal growth factor on synthesis of prostaglandins and cyclic AMP by embryonic palate mesenchymal cellsBiochemical and Biophysical Research Communications, 1985
- Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 1985
- Biosynthesis of 5,6-dihydroxyprostaglandin E1, and F1α from 5,6-dihydroxyeicosatrienoic acid by ram seminal vesiclesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1984
- Metabolism of 5(6)Oxidoeicosatrienoic acid by ram seminal vesicles. Formation of two stereoisomers of 5-hydroxyprostaglandin I1.Journal of Biological Chemistry, 1984
- Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.Journal of Clinical Investigation, 1983
- Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex.Proceedings of the National Academy of Sciences, 1981
- Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid.Proceedings of the National Academy of Sciences, 1981
- Factors controlling the proliferative rate, final cell density, and life span of bovine vascular smooth muscle cells in culture.The Journal of cell biology, 1981
- Epidermal growth factor stimulates prostaglandin biosynthesis by canine kidney (MDCK) cellsBiochemical and Biophysical Research Communications, 1977
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951